Dr. Tao Yin 尹涛
Chief Physician
Department of Hepatobiliary and Pancreatic Oncology, Hubei Cancer Hospital, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of liver, biliary, and pancreatic tumors, including complex liver resections, hilar cholangiocarcinoma, gallbladder cancer, and pancreatic tumors. Manages conversion therapy and surgery for initially unresectable colorectal liver metastases. Uses minimally invasive techniques for advanced gastrointestinal malignancies.
Dr. Yin is Chief Physician and Director of Hepatobiliary and Pancreatic Surgery at Hubei Cancer Hospital, with over 30 years of experience. A graduate of Wuhan University Medical College, Dr. Yin specializes in complex liver resections and pioneered hepatic pedicle transection anatomical segmentectomy in China. Research includes chronotherapy for colorectal liver metastases and portal vein embolization.
Professional roles
- Standing Committee Member, Biliary Tract Tumor Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Liver Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Liver Cancer Professional Committee, Hubei Anti-Cancer Association
- Editorial Board Member, Journal of Cancer Control and Research; Chinese Journal of General Surgery
Name order: in Chinese the family name comes first (Yin Tao). Papers usually list the name as Tao Yin or Yin T.
Selected publications
25 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biomed Pharmacother, 2023 (first author): Retraction notice to "ATPase inhibitory factor 1 is a prognostic marker and contributes to proliferation and invasion of human gastric cancer cells" [Biomed. Pharmacother. 70 (2015) 90-96]. PubMed 36725466
- Transl Cancer Res, 2020 (first author): Chemotherapy for breast cancer progresses to liver metastases after surgery and systemic treatment. PubMed 35117444
- Onco Targets Ther, 2019 (senior author): G3BP1 activates the TGF-β/Smad signaling pathway to promote gastric cancer. PubMed 31564899
- Biomed Pharmacother, 2015 (first author): RETRACTED: ATPase inhibitory factor 1 is a prognostic marker and contributes to proliferation and invasion of human gastric cancer cells. PubMed 25776485
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion